Baseline parameters in patients with stable renal function or progressive renal failure at the end of observation
| Stable renal function | Progressive renal failure | P value | |
| Patients, n (%) | 57 | 19 | |
| Female gender, n (%) | 38 (66.7) | 13 (68.4) | ns |
| Age at AA (years), mean (SEM) | 55.3 (2.0) | 59.4 (2.2) | ns |
| Age at disease onset (years), mean (SEM) | 36.1 (3.0) | 39.7 (4.9) | ns |
| Treatment V1 to last visit (years), mean (SEM) | 5.0 (0.8) | 4.9 (0.9) | ns |
| Primary disease, n (%) | |||
| Arthritis | 10 (17.5) | 6 (31.6) | ns |
| IBD | 4 (7.0) | 3 (15.8) | |
| Other | 4 (7.0) | 3 (15.8) | |
| Idiopathic | 18 (31.6) | 4 (21.1) | |
| Autoinflammatory syndrome | 21 (36.8) | 3 (15.8) | |
| Concomitant disease, n (%) | ns | ||
| Arterial hypertension | 25 (43.9) | 6 (31.6) | |
| Diabetes mellitus type 2 | 1 (1.8) | 2 (10.5) | |
| Metabolic syndrome | 4 (7.0) | 1 (5.3) | |
| None | 27 (47.4) | 10 (52.6) | |
| FAB CR stain at V1 | ns | ||
| 3+ (10%–60% area) | 3 | 3 | |
| 2+ (1%–10% area) | 5 | 2 | |
| 1+ (<1% area) | 20 | 9 | |
| 0 | 10 | 5 | |
| Not done | 12 | 7 | |
| Serum creatinine at V1, mean (SEM) | 1.57 (0.1) | 3.06 (0.35) | 0.0001 |
| Serum creatinine <2.5 mg/dL at V1, n (%) | 42 (73.7) | 8 (42.1) | 0.024 |
| Protein to creatinine ratio at V1, mean (SEM) | 759.2 (226.8) | 1428.7 (403.8) | 0.021 |
| Protein to creatinine ratio <300 g/mol at V1, n (%) | 18 (31.6) | 2 (10.5) | ns |
| CRP at V1, mean (SEM) | 37.6 (5.3) | 22.2 (3.6) | ns |
| CRP at last visit (<5 mg/L) | 10.8 (2.7) | 7.9 (1.6) | ns |
| P value V1 vs last visit | 0.0001 | 0.0049 | |
| SAA at V1, mean (SEM) | 83.4 (20.0) | 57.3 (21.2) | ns |
| SAA at last visit (<8.6 mg/L) | 14.2 (4.2) | 19.6 (8.2) | ns |
| P value V1 vs last visit | 0.0001 | 0.0068 | |
| BMI (kg/m2), mean (SEM) | 28.79 (3.59) | 27.83 (3.67) | ns |
| SAA1α/α, n (%) | 35 (77.8) | 8 (72.7) | ns |
AA, AA amyloidosis; BMI, body mass index; CRP, C reactive protein; IBD, inflammatory bowel disease; SAA, serum amyloid alpha; V1, visit 1.